Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 5 (2008), Issue 3 (March)

1. Preclinical modeling of endocrine response and resistance : focus on aromatase inhibitors.
   Cancer, 112: 679-688. [Abstract] [Full-text]
2. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
   J Clin Oncol, 26(7): 1066-72. [Abstract] [Full-text]
3. In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine.
   Breast Cancer. [Abstract] [Full-text]
4. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.
   Cancer Res, 68(5): 1538-45. [Abstract] [Full-text]
5. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.
   Cancer Res, 68(5): 1471-7. [Abstract] [Full-text]
6. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab.
   Int J Cardiol, 125(1): 113-5. [Abstract] [Full-text]
7. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
   J Clin Oncol, 26(8): 1231-8. [Abstract] [Full-text]
8. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
   J Clin Oncol, 26(8): 1216-22. [Abstract] [Full-text]
9. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety.
   Crit Rev Oncol Hematol, 66(1): 31-41. [Abstract] [Full-text]
10. ErbB-directed immunotherapy: Antibodies in current practice and promising new agents.
    Immunol Lett, 116(2): 126-40. [Abstract] [Full-text]
11. HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetization.
    Biomaterials, 29(14): 2270-9. [Abstract] [Full-text]
12. Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
    Ann Oncol. [Abstract] [Full-text]
13. Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab.
    Pharmacoepidemiol Drug Saf. [Abstract] [Full-text]
14. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs.
    J Immunol Methods, 332(1): 41-52. [Abstract] [Full-text]
15. Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage.
    J R Soc Med, 101(3): 125-32. [Abstract] [Full-text]
16. Life-threatening interstitial lung disease associated with trastuzumab: case report.
    Breast Cancer Res Treat. [Abstract] [Full-text]
17. Breast cancer subtypes and survival in patients with brain metastases.
    Breast Cancer Res, 10(1): R20. [Abstract] [Full-text]
18. Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines.
    Cancer Treat Rev. [Abstract] [Full-text]
19. Emerging therapeutic options for breast cancer chemotherapy during pregnancy.
    Ann Oncol, 19(4): 607-13. [Abstract] [Full-text]
20. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
    Cancer Chemother Pharmacol. [Abstract] [Full-text]
21. Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu(+) tumors.
    Cancer Chemother Pharmacol. [Abstract] [Full-text]
22. Targeted therapies for patients with germ cell tumors.
    Expert Opin Investig Drugs, 17(4): 511-22. [Abstract] [Full-text]
23. Implications of EGFR PharmDx kit for cetuximab eligibility.
    Expert Rev Mol Diagn, 8(2): 141-8. [Abstract] [Full-text]
24. Is triple negative a prognostic factor in breast cancer?
    Breast Cancer. [Abstract] [Full-text]
25. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
    J Clin Oncol, 26(10): 1642-9. [Abstract] [Full-text]
26. Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies.
    Biochim Biophys Acta. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.